Purified tumor samples from 9/12 patients responded to 72 hours treatment of 4 μM UNC1999 with 40% to 75% decrease in the number of viable CD138+ myeloma cells as compared with UNC2400 treatment. This evidence concerns the gene SDC1 and plasma cell myeloma.